Group items tagged

"In the past few weeks, the blogosphere has been abuzz about the dangers of non-replication and the "decline" effect, triggered by Jonah Lehrer's interesting piece in the New Yorker (mostly behind a firewall). The central claim in the piece is that initially strong or provocative findings diminish in strength over time. The decline might well come from more stringent methodology or better experimental controls rather than via mysterious forces, but that's not what concerns me today. My concern is about media reporting and even blogging about new and provocative scientific findings, the very findings that tend to decline. Following a murder, the arrest of a suspect is broadcast on the front pages, but when that suspect is exonerated, the correction ends up on the back of the local section months later (if it appears at all). The same problem holds for flawed scientific claims. The thoroughly debunked Mozart Effect still receives media coverage, just as other unsupported findings remain part of the popular consciousness despite a lack of replicability."

"n September 18, 2007, a few dozen neuroscientists, psychiatrists, and drug-company executives gathered in a hotel conference room in Brussels to hear some startling news. It had to do with a class of drugs known as atypical or second-generation antipsychotics, which came on the market in the early nineties. The drugs, sold under brand names such as Abilify, Seroquel, and Zyprexa, had been tested on schizophrenics in several large clinical trials, all of which had demonstrated a dramatic decrease in the subjects' psychiatric symptoms. As a result, second-generation antipsychotics had become one of the fastest-growing and most profitable pharmaceutical classes. By 2001, Eli Lilly's Zyprexa was generating more revenue than Prozac. It remains the company's top-selling drug. But the data presented at the Brussels meeting made it clear that something strange was happening: the therapeutic power of the drugs appeared to be steadily waning. A recent study showed an effect that was less than half of that documented in the first trials, in the early nineteen-nineties. Many researchers began to argue that the expensive pharmaceuticals weren't any better than first-generation antipsychotics, which have been in use since the fifties. "In fact, sometimes they now look even worse," John Davis, a professor of psychiatry at the University of Illinois at Chicago, told me. "